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ABSTRACT
Background and aim: the success of colorectal cancer (CRC) 
screening programmes largely depends on the quality of the events, 
processes and outcomes and therefore, quality assurance of endos-
copy is an essential component. The quality indicators for colonos-
copy in a screening programme setting are different from those 
performed in symptomatic people. The objective of this study was 
to report the main quality indicators of colonoscopies performed 
after a positive faecal occult blood test (FOBT) in a CRC screening 
programme in Catalonia.
Methods: the period of study includes three rounds of the CRC 
screening programme from June 2006 to July 2013. Two types 
of FOBT were used: a qualitative biochemical guaiac-based test 
(gFOBT) and a quantitative immunochemical test (FIT). Quality 
indicators analysed in this study were compared to recommended 
colonoscopy standards from the published guidelines.
Results: during the study period, 1,806 colonoscopies were 
performed in 1,691 individuals with a positive FOBT. All indica-
tors were within the standard except waiting time to colonoscopy. 
Caecal intubation rate was 95.6 % and adequate bowel cleansing 
93.6 %. Adenoma detection rate was better using FIT than gFOBT, 
30.7 and 3.8 per 1,000 screenees, respectively. Cancer detection 
rate was also greater using FIT. Nearly 62 % of cancers were diag-
nosed at an early stage. The overall complication rate was 10.7 ‰.
Conclusion: although the majority of results reached the rec-
ommended standards, some areas have been identified for qual-
ity enhancement. Continuous monitoring of quality indicators is 
essential for improving the current effectiveness of CRC screening 
programmes.
Key words: Colonoscopy. Quality indicators. Colorectal cancer. 
Mass screening programme.
INTRODUCTION
Colorectal cancer (CRC) is the third most common can-
cer in Europe and is one of the leading causes of cancer 
death. An estimated 432,414 new CRC cases and 212,219 
CRC deaths occur annually, which represents an age-stan-
dardized rate of 29.6 and 12.4 per 100,000, respectively 
(1). In Spain, CRC is the most incident cancer when con-
sidering both sexes together. There is a marked geographic 
variation in CRC rates, with Catalonia being the region 
with the highest incidence of this tumour with an adjusted 
rate above the European average, particularly in men (2,3).
Screening for early detection of CRC and its premalig-
nant precursors with the faecal occult blood test (FOBT) 
has demonstrated efficacy in reducing mortality and is the 
recommended strategy in the European Union (4,5). During 
the last decade, organised CRC screening programmes have 
been increasingly adopted throughout Europe (6,7). In Spain, 
CRC screening programmes are implemented and managed 
on a regional basis. In 2000, the first population-based pilot 
screening programme for CRC using biennial FOBT was 
implemented in Catalonia (8). At present, twelve out of 17 
Spanish regions have initiated screening programmes, 8 of 
them with results of at least one screening round (9). There 
is consensus regarding the need to extend this preventive 
task to the whole country in the coming years (10). 
The success of screening programmes largely depends 
on the participation achieved and the quality of the pro-
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cedures used. Thus, the adoption of quality improvement 
measures and continuous quality assessment is impera-
tive to improve the current effectiveness of CRC screening 
programmes (11,12). A very important point in this sense 
is the colonoscopy, which is a procedure that is not only 
diagnostic but also therapeutic. Colonoscopy in the screen-
ing context must be performed according to high-quality 
standards, especially regarding detection rates and safety 
(13-15). Individuals with a normal colonoscopy will be 
temporarily excluded from the screening programme, usu-
ally for a 10-year period, which means a lack of prevention 
for CRC when the diagnostic colonoscopy has been sub-
optimal and lesions have been overlooked. Measurement 
of quality indicators for colonoscopy reporting can help us 
identify areas for quality improvement.
The objective of this study was to report the main qual-
ity indicators of colonoscopies performed in three rounds 
of the CRC screening programme in Catalonia, Spain.
METHODS
The CRC screening programme was addressed at 
asymptomatic men and women aged 50-69 years who 
lived in L’Hospitalet de Llobregat, an industrial city in 
the metropolitan area of Barcelona. Subjects who did not 
meet the inclusion criteria for CRC screening were defi-
nitely or temporally excluded according to the following 
criteria: Personal history of CRC or adenomas, hereditary 
and familial CRC, inflammatory bowel disease, colonos-
copy in the previous 5 years, FOBT in less than 2 years, 
terminal disease and severe disabling condition. Subjects 
moving out of the screening area or whose invitation letter 
was returned because of an invalid mailing address were 
also excluded (16).
The period of study includes three rounds of the CRC 
screening programme, from June 2006 to July 2013. Two 
screening test strategies were used along that period. A 
qualitative biochemical guaiac-based test (gFOBT) was 
used in the third and fourth round (Hema-screenTM, immu-
nostics.inc), and a quantitative faecal immunochemical test 
(FIT), which was introduced as an alternative test in the 
fourth round and remained as the only strategy for the fifth 
round (OC Sensorμ, Palex) (17). Participants with gFOBT 
collected six faecal samples (two samples from three sep-
arate bowel movements) whereas only one sample was 
needed with FIT. The presence of faecal occult blood in 
five or six samples (or in any sample after retesting) and 
a cut off of 100 ng/mL were used to designate a positive 
FOBT result, for gFOBT and FIT respectively. All par-
ticipants with a positive test result were advised to have 
colonoscopy. 
The study population consisted of participants in the 
CRC screening programme during the study period with a 
positive FOBT who were offered a colonoscopy for diag-
nostic confirmation (Fig. 1). 
Procedure for further screening examination
All screenees with a positive FOBT were contacted by 
phone to provide information regarding the screening result 
and to advise them that they will be referred for colonos-
copy examination. A preoperative evaluation was routinely 
required (haemostasis test and electrocardiogram for all 
individuals and a chest x-ray only for individuals older 
than 64 years or with a chronic disease). In addition to the 
preoperative exams, bowel-cleansing preparation was pro-
vided by primary health centres, either polyethylene glycol 
or sodium phosphate. Colonoscopies were scheduled in the 
afternoon on a specific agenda, taking the bowel-cleansing 
preparation the same morning, with 6 h complete fasting 
until the examination. For those who chose the private prac-
tice, a postage paid envelope was provided by the screening 
programme in order to receive a copy of the colonoscopy 
report. All the available information was included in the 
CRC screening programme, and therefore, in the analysis.
Four days prior to colonoscopy, patients were called to 
remind them about the appointment and to provide instruc-
tions for the bowel preparation. 
Colonoscopies were performed with sedation on an 
outpatient basis at the Endoscopy Unit of the two coun-
Fig. 1. Flow chart of the study population.
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ty Hospitals of L’Hospitalet by an expert team including 
a gastroenterologist, an anaesthesiologist, a nurse and a 
nurse’s aide. 
During the study period, a total of 16 gastroenterologists 
were part of the programme, some of them repeated round 
by round and other only took part in a short period of time 
or a specific round. The gastroenterologist screening team 
was composed by specialists, which are the ones who fulfil 
the experience criteria. All endoscopists achieved the min-
imum number of colonoscopies required before joining the 
screening programme. 
Propofol was the drug used for sedation and was admin-
istered by the anaesthesiologists. Any detected polyp was 
described and removed when endoscopically possible. 
Number, size (mm), morphology (pedunculated, sessile or 
flat) and location (rectum, sigmoid, descending, transverse, 
ascending or caecum) were documented. Location was 
recoded as proximal (caecum, ascending and transverse) 
or distal (descending, sigmoid and rectum). 
For incomplete colonoscopies, patients were offered a 
new attempt of colonoscopy or another diagnostic explora-
tion, usually a barium enema. Subjects with cancer or pol-
yps too large or complicated to be removed endoscopically 
were referred to surgery. Major immediate complications 
were also documented.
Polyp specimens and biopsies were analysed by pathol-
ogists and classified according to World Health Organi-
zation criteria, considering a high risk adenoma (HRA) 
or advanced adenoma any polyp larger than or equal to 
10 mm, more than 2 adenomas, tubulo-villous or villous 
histology, high-grade dysplasia or carcinoma in situ; low 
risk adenoma (LRA), 1 or 2 adenoma smaller than 10 
mm, with tubular histology and low grade dysplasia. The 
criterion for cancer diagnosis was an invasion of malig-
nant cells beyond the muscularis mucosa. Tumour staging 
was performed according to the tumour node metastasis 
(TNM) system, which was gathered from the anatomic 
pathology result of the cancerous lesion and the extension 
study. Early-stage cancers were those classified as I or 
II according to the TNM system. Cases with more than 
one lesion were classified according to the most advanced 
lesion. 
Follow-up colonoscopy was recommended to patients 
with adenomatous polyps detected in the screening pro-
gramme. According to the Spanish CRC prevention prac-
tice guideline (18) a surveillance colonoscopy was recom-
mended at 3 or 5 years when the baseline diagnostic was 
HRA and LRA, respectively. Cancers were referred to the 
tumour committee to begin treatment as soon as possible. If 
no adenomatous polyp was found, subjects would be invited 
again for screening with FOBT or a surveillance colonosco-
py would be recommended after 10 years, according to age. 
According to the result of the colonoscopy and polyp 
characteristics (number, size, histology and grade of dys-
plasia), each patient was classified in: normal colonoscopy, 
hyperplasic polyp, LRA, HRA, or cancer.
Data collection and analysis
The information system to manage the CRC screening 
programme included data on patient identification, partici-
pation, appointment dates, screening test and colonoscopy 
results. 
Quality indicators analysed in this study were classified 
according to the endoscopic examination in three groups: 
pre-procedure, procedure and post-procedure (19).
The pre-procedure period starts with the first contact 
with the patient until administration of sedation. We con-
sidered the following pre-procedural indicators: a) colo-
noscopy compliance defined as the proportion of people 
with a positive FOBT who underwent colonoscopy; b) 
time interval (days) to colonoscopy after a positive FOBT. 
This was assessed using the proportion of screenees who 
were scheduled for a colonoscopy within 31 days; and c) 
sedation use, calculated as the proportion of colonoscopies 
performed under sedation.
The procedure refers to the colonoscopy examination 
(from insertion to withdrawal). We calculated procedural-re-
lated indicators (events and processes) as well as procedural 
outcomes: a) bowel cleansing, using the Aronchick scale 
(20) (Excellent/Good/Fair/Poor/Insufficient). All cases were 
categorized at the end of the procedure as “adequate exam-
ination” (Excellent/Good/Fair), or “not adequate examina-
tion” (Poor/Insufficient); b) caecal intubation rates, calcu-
lated as the proportion of colonoscopies that reached the 
caecum. Visualization of the ileocaecal valve and/or intu-
bation of the terminal ileum provided reassurance of the 
procedure’s completeness; c) polyp-retrieval rate, calculated 
as the proportion of retrieved polyps from those removed; 
d) time interval (days) to the anatomic pathology result after 
the colonoscopy; e) adenoma and CRC positive predictive 
value (PPV), defined as the proportion of colonoscopies in 
which an adenoma or a CRC was found (documented on the 
anatomic pathology report); f) adenoma and CRC detection 
rate defined as the number of adenomas or CRC detected 
among those screened (FOBT done); and g) proportion of 
CRC diagnosed at an early stage.
Detection rates and PPV were analyzed by test (gFOBT 
vs. FIT) and by type of screening (prevalent or first screen 
vs. incident or subsequent screen). 
Post-procedure: The adverse effects recorded were: per-
foration and post-polypectomy bleeding (involving trans-
fusion or hospitalisation of at least 24 hours) and death 
(within 30 days).
Quality indicators calculated for this study were com-
pared with standards proposed by the “European Guide-
lines for Quality Assurance in Colorectal Cancer Screening 
and Diagnosis” (21), the Spanish “Clinical Practice Guide-
line: Quality of Colonoscopy in CRC Screening” (22).
Due to differences in some terms and indicators among 
health professionals (endoscopists and epidemiologists), 
main definitions and measures of each indicator used in our 
screening programme are shown in the Appendix.
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RESULTS
From June 2006 to July 2013, 1,806 colonoscopies were 
performed in 1,691 individuals with a positive FOBT in 
the CRC screening programme of l’Hospitalet de Llobre-
gat. The results of colonoscopies were: 31.4 % negatives 
(without any kind of lesion), 4.2 % hyperplasic polyps, 
13.3 % LRA, 43.8 % HRA and 7.3 % cancer.
The main quality indicators related to colonoscopy and 
the standards established in the different guidelines men-
tioned are showed in table I.
Pre-procedure indicators
Colonoscopy compliance 
From the 1,876 individuals with a positive FOBT, colo-
noscopy was not recommended in 77 cases due to medical 
criteria. The main reason was having a recent exploration. 
Thus, 1,799 people were referred to colonoscopy and the 
compliance was 94.0 % (Fig. 1). Most people had only 
one colonoscopy performed but 7.5 % needed a second 
one or other examinations. The most common reason was 
an incomplete polypectomy (i.e. the polyp size) or a pol-
ypectomy indication in patients receiving anticoagulant or 
anti-platelet agents without discontinuing the treatment 3-7 
days prior to the colonoscopy. 
Waiting time to colonoscopy 
The median waiting time between the positive FOBT 
result and the colonoscopy was 55 days (range 38-69 days). 
Only the 14.2 % of patients had the colonoscopy performed 
within the European guideline standard of 31 days. 
Sedation use
All except seven colonoscopies (3 for self-request, 2 
for liquid intake within the 6 hours prior to colonoscopy, 1 
for going on his/her own and 1 unknown) were done with 
sedation, which represented 99.6 %.
Intra-procedure indicators
Bowel cleansing and caecal intubation
Adequate colonic cleansing was observed in the 93.6 % 
of cases. The bowel preparation most frequently used was 
the polyethylene glycol. 
The caecal intubation rate was within the range set by the 
European guidelines as desirable (95.6%). The most common 
reason for not reaching the caecum was stenosis (20 cases). 
Polyp-retrieval 
In 1,806 colonoscopies, 2,774 polyps were detected 
and 2,404 removed. The polyp-retrieval rate was 86.7 %, 
being higher for polyps larger than or equal to 10 mm 
(96.5 %) than for polyps smaller than 10 mm (82.6 %). 
These results met the standard of the gastroenterologist’s 
clinical guidelines.
Adenomas and cancers detected: PPV and detection rates
In 90.0 % of colonoscopies, the anatomic pathology 
report of the polyps removed was obtained within 19 days. 
A final diagnosis of adenoma was established in 960 
patients (737 HRA and 223 LRA), which represented a 
PPV of 44.6 % for gFOBT and a 59.5 % for FIT. 
Detection rates and PPV exceeded the standard values 
of both reference guidelines.
The adenoma detection rate was much higher in the FIT 
group than in the gFOBT, 30.7 and 3.8 per 1,000 screenees, 
respectively, and was also higher in initial than successive 
screening irrespectively of the test used. 
Considering that carcinoma in situ was not classified 
as cancer, 122 adenocarcinomas were confirmed, 40 with 
gFOBT and 82 with FIT. The overall cancer detection rate 
was more than two-fold with the FIT (3.0 ‰) compared to 
the gFOBT (1.2 ‰). Cancer detection rate in initial scre-
enees was greater than in subsequent.
Near 62 % of cancers were diagnosed at an early stage 
with clear differences regarding the screening group 
(47.8 % in initial screening vs. 69.7 % in successive 
screening). 
Post-procedure indicators
Colonoscopy complication
Eighteen severe complications were detected by the 
screening programme along the period of study: 3 perfo-
rations and 15 lower gastrointestinal bleeding. This rep-
resented an overall complication rate of 10.7 ‰ which is 
stated as acceptable according to the range established in 
the European Guideline but not according to the Spanish 
Clinical Guideline.
DISCUSSION
This paper analyses the main quality indicators relat-
ed to colonoscopy of three screening rounds of the first 
population-based CRC screening programme implemented 
in Spain. All indicators were within the standard except 
waiting time to colonoscopy.
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Many attempts have been made to define useful quality 
indicators through the implementation and consolidation 
of screening programmes. In recent years, its use has been 
gradually extended and finally accepted by different pro-
fessional societies. However, there is still much work to do 
to in order to ensure everyone is using the same definitions 
and standard values. As shown in this study, from the infor-
mation sources used, reference values differ on some cri-
Table I. Quality indicators related to colonoscopy
Catalan Screening Programme* European Guidelines (21) Gastroenterologist´s 
Clinical Guidelines*** 
(22)
Colonoscopy 
compliance 
94.0% > 85 % acceptable; > 90 % desirable -----
Waiting time to 
colonoscopy 
14.2 % within ≤ 31 days > 90 % within ≤ 31 days acceptable
> 95 % within ≤ 31 days desirable
< 6 weeks
Sedation use 99.6 % ----- > 90 %
Adequate bowel 
cleansing 
93.6 % ----- > 90 % with 
good or excellent 
preparation
Caecal intubation 95.6 % > 90 % acceptable; > 95 % desirable > 95 %
Polyp-retrieval 
rate
Overall: 86.7 %
96.5 % polyps ≥ 10 mm
82.6 % polyps < 10 mm
-----
-----
> 95 % polyps ≥ 
10 mm
> 80 % polyps < 
10 mm
Waiting time to 
pathology result
98.1 % within ≤ 31 days > 95 % within ≤ 31 days -----
Early stage 
cancers (I and II)
61.5 % Favourable -----
Complication 
rate
Overall: 10.7 ‰
Perforation: 1.8 ‰
Postpolypectomy bleeding: 8.9 ‰
Overall: 5.0-16.0 ‰
-----
-----
-----
Perforation: < 
1.0 ‰
Postpolypectomy 
bleeding < 5.0 ‰
gFOBT FIT gFOBT FIT
n PPV Detection
rates
n PPV Detection
rates
PPV Detection
rates
PPV Detection
rates
Adenomas detected (HRA, LRA)
Initial screening 55 51.4 % 5.3 ‰ 304 59.7 % 35.8 ‰ ----- 5.2-
10.5 ‰
19.6-
40.3 %
13.3-
22.3 ‰
-----
Successive 
screening
68 40.2 % 3.1 ‰ 533 59.4 % 28.9 ‰ ----- 3.3-4.7 
‰
----- ----- -----
Total 123 44.6 % 3.8 ‰ 837 59.5 % 30.7 ‰ 30.3 % ----- ----- ----- PPV > 40 %**
Cancer detected
Initial screening 16 15.0 % 1.5 ‰ 30 5.9 % 3.5 ‰ 6.2-8.5 
%
1.2-2.3 
‰
4.5-8.6 
%
1.8-9.5 
‰
-----
Successive 
screening
24 14.2 % 1.1 ‰ 52 5.8 % 2.8 ‰ 5.3-
10.6 %
0.9-
0.94 ‰
4.0 % 1.3 ‰
Total 40 14.5 % 1.2 ‰ 82 5.8 % 3.0 ‰
*Screenees with follow-up colonoscopy (n = 1,691); colonoscopies performed (n = 1,806); polyps detected (n = 2,774) and cancers (n = 122). **Detection 
rate according to endoscopist´s definition. ***Sedation use, caecal intubation, polyp-retrieval rate and complication rate were not calculated by endoscopists 
despite Gastroenterologist´s Clinical Guidelines recommendation. HRA: high risk adenoma; LRA: low risk adenoma; PPV: positive predictive value; gFOBT: guaiac 
faecal occult blood test; FIT: Immunochaemical faecal occult blood test.
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teria and the definitions were not exactly the same, which 
makes it difficult to compare between different screening 
programmes. We chose the published guidelines (21,22) 
for our comparison and analysis because they were devel-
oped through a consensus and peer-review process. 
The effectiveness of a colonoscopy depends on the 
adequate visualization of the entire colon which relies on 
bowel cleansing and the expertise of the endoscopist in 
performing careful examinations in order not to miss any 
lesion, reach the caecum and remove all the polyps detect-
ed (11,23). Various studies suggest that some endoscopists 
could leave up to half of the adenomas undiagnosed (24). 
A difference of up to 20 % has been described in the pro-
portion of colonoscopies with at least one adenoma and 
up to 9 times in the proportion of patients with advanced 
adenomas (25-27). In this context, where the detection of 
lesions is crucial, each endoscopist must be an experienced 
examiner, having performing a minimum of procedures 
annually and before entering the screening program (22). 
Colonoscopy compliance is a key indicator to consider 
in the effectiveness of the programme. We obtained good 
results which might be partially due to the sedation use 
(risk of discomfort may impact adversely on the accep-
tance) and also due to the follow-up done by the screening 
technical office to all people with a positive FOBT. 
The time interval from a positive FOBT to colonoscopy 
was one of the worse process indicators in our screening 
programme. Although prolonged waiting time for colo-
noscopy has not been associated with an increase in the 
proportion of late-stage cancers diagnosed, it is associated 
with higher levels of anxiety. For this reason, the guide-
lines recommend a maximum benchmark of one month 
set as desirable. The Catalonian Advisory Group for the 
CRC Screening Programme has established this indicator 
in 60 days. According to this, we increased to 58.0 % the 
population with a colonoscopy performed within 60 days.
In our study, adequate bowel cleansing was one of the 
highest rates reported in a screening programme (28,29). 
We think that this excellent result is because of the exhaus-
tive work done by the administrative staff who widely 
explained the whole process for a good bowel-cleansing 
and made a reminder some days previous to the colonos-
copy appointment.
Missing lesions may be attributed to inadequate bowel 
preparation, an incomplete procedure, or failure to iden-
tify a lesion due to inadequate time spent examining the 
colonic mucosa (30). Inadequate bowel preparation not 
only limits the visibility of the mucosa and prolongs caecal 
intubation and withdrawal time, it also leads to a shorter 
interval for the next exam (19). Nevertheless, the quality 
of bowel cleansing is a subjective measure and efforts to 
increase reproducibility and validity are needed (31).
Colonoscopy completion rate is associated with seda-
tion as the patient’s welfare eases an entire exploration. 
The need for caecal intubation is based on the findings that 
an important number of CRC (near 30 %) are located in the 
proximal colon. According to the colonoscopy report, more 
than 95.6 % of the screening programme colonoscopies 
reached the caecum. However, this information was not 
supported by photo documentation as the guidelines on 
quality assurance of colonoscopies suggested. 
Every lesion detected during colonoscopy must be 
removed and analysed, independently of its size. However, 
small polyps are harder to remove, which emphasise the 
importance of having expert colonoscopists with sufficient 
technical skill in the screening programmes. 
The PPV for adenoma was above the standard and has 
been increasing from the first round (30.2 %) to the last 
one (60.9 %). This is a very good result because a low PPV 
indicates less false positive results. A high proportion of 
false-positive results leads to unnecessary colonoscopies 
with associated costs and risks. Factors associated with a 
false-positive result in the Catalan CRC Screening Pro-
gram were: Being women (more than a twofold likelihood 
than men), the first prevalence round and the successive 
screening (32).
Regarding detection rates, it is important to note that 
endoscopists refer to detection rate, what epidemiologists 
refer to as positive predictive value. In this article, we use the 
epidemiologist definitions. Positive predictive value takes 
into account the lesions detected among those with a positive 
FOBT result who underwent a colonoscopy, while detection 
rate takes into account lesions detected among people who 
have had a screening test (see definitions in Appendix).
Consistent with previous results (33-35), FIT obtained 
much better detection rates than the gFOBT. Our results 
should be interpreted carefully when compared with other 
screening programmes. The Italian CRC screening pro-
gramme (36), with 4 rounds completed, has always used 
the FIT as screening test. On the contrary, the English pro-
gramme (37), has used the guaiac in its three concluded 
rounds. In our programme two tests were simultaneously 
used and we have to take into account that some people 
who participated with FIT, had used the guaiac in the pre-
vious round. 
Most cancers were diagnosed at an early stage. How-
ever, we consider that achieving a high detection rate for 
pre-neoplastic advanced lesions is even more relevant 
because these lesions could progress to cancer in the near 
future. It is also important to note that, unlike other screen-
ing programme protocols, the Catalan CRC screening pro-
gramme does not include carcinoma in situ in the cancer 
group, which would increase cases of cancer at early stage.
According to the European Guideline (21), major com-
plications (perforation and bleeding) occur in 3 ‰ of colo-
noscopies in a high-quality CRC screening programme 
using colonoscopy as a primary screening test. On the 
other hand, the standard regarding major complications 
in programmes based in FOBT screening is 5.0-16.0 ‰. 
This higher complication rate is because colonoscopies 
are performed in individuals with a positive screening test 
(FOBT), which makes it more probable that they will have 
406 G. BINEFA ET AL. Rev esp enfeRm Dig (maDRiD)
Rev esp enfeRm Dig 2013; 105 (7): 400-408
a neoplastic lesion, hence the need for polypectomy and 
therefore an upper risk of perforation.
The complication rate could be underestimated because 
perforations may only be apparent after the patient has 
been discharged and patients are sometimes treated in a 
different hospital. We believe it is necessary to establish 
a system to detect complications after the patient has left 
the endoscopy department. One study found that a simple 
phone call 30 days after the colonoscopy identified more 
delayed complications than was previously known about 
(38). Our screening programme is working on a telephone 
survey to get information about complications that may 
arise before, during or after the colonoscopy. 
Although colonoscopy withdrawal time is considered 
an important quality indicator, at the moment our screen-
ing programme does not collect this information. We are 
working to incorporate this indicator in the CRC screening 
software, as well as other that were not contemplated when 
the screening was implemented in 2000.
Effective quality assurance is critical to ensure that the 
benefits of screening outweigh the harms and it is a very 
important aspect in the screening program which invites 
healthy people who have no symptoms of CRC and have 
different expectations than symptomatic patients (39).
In conclusion, although the Catalan Colorectal Cancer 
Screening programme achieved the standard values in 
the majority of colonoscopy key indicators, there are still 
some areas to improve. To achieve good results we must 
work together with all the professionals involved. There 
is a long way and the first step should be the accreditation 
of the endoscopy units of the colorectal cancer screening 
programme. 
Appendix. Colorectal cancer screening measures and indicators* 
Screening measures Indicators
Eligible = A1
Total number of people eligible for screening according to the program policy
Missed invitations = A0
Total number of eligible people who did not receive the screening invitation (wrong address)
Invited = A2 = A1 – A0
Total number of people who received an invitation for screening according to the program policy
Tested = B 
Total number of people who have used and returned an FOBT kit irrespective of result. This includes 
people with inadequate/incomplete results. Note that each person is counted once regardless of the 
number of tests performed
Participation (%) = (B / A2) * 
100
Adequately tested = C
Total number of people who have returned an FOBT and achieved a conclusive result (positive or 
negative)
Positive FOBT = D 
Total number of people who have a positive result with FOBT
Positivity (%) = (D / C) * 100
Referred to colonoscopy = E
Total number of people presenting with a positive FOBT and referred for colonoscopy
Diagnostic/therapeutic colonoscopy = F
Total number of people who have undergone a colonoscopy, including those whose colonoscopy 
was inadequate/ incomplete. Note that each person is counted once regardless of the number of 
colonoscopies performed
Colonoscopy compliance (%) = 
(F / E) * 100
Date of positive FOBT result = G 
Date of colonoscopy after positive screening = H 
We used the date recorded by the laboratory after analysing the FOBT and the date when the 
colonoscopy was performed
Waiting time to colonoscopy 
(days) = H - G
Sedation = I
Total number of people who have undergone a colonoscopy under sedation (Propofol)
Sedation use (%) = (I / F) * 100
Colonic cleansing = J
Total number of people who have undergone a colonoscopy, with adequate colonic cleansing (mucosa 
well seen throughout or with liquid content easily suctioned)
Adequate colonic cleansing (%) 
= (J / F) * 100
Caecal intubation = K
Total number of complete colonoscopies (complete intubation of the colon and to carefully inspect the 
mucosa during withdrawal)
Caecal intubation (%) = (K / F) 
* 100
(continuation in next page)
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Appendix. Colorectal cancer screening measures and indicators* (continuation)
Screening measures Indicators
Polyps removed = L1
Total number of polyps detected from one colonoscopy
Polyps retrieved = L2
Total number of polyps retrieved from those detected from one colonoscopy
Polyp-retrieval (%) = (L2 / L1) 
* 100
Date of pathology results = M 
We used the date of the pathology result after a colonoscopy with polypectomy
Waiting time to colonoscopy 
pathology results (days) = M - H
Colonoscopy complications = N
Total number of severe complications such as perforation and post-polypectomy bleeding (involving 
transfusion or hospitalisation of at least 24 hours) and death (within 30 days)
Colonoscopy complications (‰) 
= (N / F) * 1000
Cancers = O 
Total number of people diagnosed with colorectal cancer by or as a direct result of the screening 
program
Cancer detection rate (‰) = 
(O / C) * 1000
PPV Cancer (%) = (O / F) * 100
HRA = P1
Total number of people whose pathological specimens removed at endoscopy or surgery has been 
reported by a pathologist to be either adenomatous polyps larger than or equal to 10 mm, more than 
2 adenomas, tubulo-villous or villous histology, high-grade dysplasia or carcinoma in situ
LRA = P2 
Total number of people whose pathological specimens removed at endoscopy or surgery has been 
reported by a pathologist to be 1 or 2 adenoma smaller than 10 mm with tubular histology and low-
grade dysplasia
HRA detection rate (‰) = 
(P1 / C) * 1000
PPV HRA (%) = (P1 / F) * 100
LRA detection rate (‰) = 
(P2 / C) * 1000
PPV LRA (%) = (P2 / F) * 100
Early-stage cancers (I and II) = Q 
Total number of screen-detected cancers that were staged as I-II using the international TNM 
classification (carcinoma in situ is classified as HRA, not cancer)
Early-stage cancers (%) = 
(Q / O) * 100
*Based on European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis – First Edition. FOBT: Faecal occult blood test; HRA: High 
risk adenoma; LRA: Low risk adenoma; PPV: Positive predictive value.
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